Boston Pharmaceuticals Inc.

Following GSK’s $1.2bn acquisition of privately held Boston Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) candidate efimosfermin on 14 May, the industry is wondering what re

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

In the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which

When Akero Therapeutics failed to meet the 36-week primary endpoint in its Phase IIb SYMMETRY study of efruxifermin in metabolic dysfunction-associated steatohepatitis (MASH) in October 2023, the comp